The shares for Aeterna Zentaris Inc. (NASDAQ:AEZS) improved by 8.16% and reached $0.0610. The EPS offered by the firm for the past five years stands at 30.4%. The company is currently working on offering treatments for oncology, endocrinology and women’s health. According to recently released reports, the independent data and safety monitoring board has given a nod for the phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study using zoptraelin doxorubicin on women. The study will continue as planned by the organization. A total of 192 events will occur as part of the phase 3.
The stocks of the firm at the markets have portrayed incredible performance as a result of this report. The firm opened at $0.064 on Tuesday at the stock markets. It closed at $0.0648 slightly higher than the opening price. The firm gained by 0.003 points which translates to 4.92% .The Company has recorded return of equity 246.8% and a ROA ratio was -56.6%. The market capitalization has been recorded at $10.63. The price to book ratio is recorded at 0.76. The stock volatility has been recorded at 10.66%. for the week, while it has been recorded at 16.55% for the past four weeks.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health.
Healthcare industry seems to be gaining at the stock markets. Shares for Great Basin Scientific Inc. (NASDAQ:GBSN) improved by 6.86% in the past week, and by 77.41% in the past four weeks. In fact, the firm outperformed at the S&P index by 5.9% in the past week and by 70.86% in the past four weeks.
The firm’s shares have seen a drop of about -98.06% in the one year high price that it recorded on the 22nd October 2014. The one year high price was $6.3. The 50 day moving average and 200 day moving average reported by the company are $0.12 and $2.39 respectively. At present, the year to date stock performance for the firm stands at -92.26%. The firm has been given a short term price update by 3 analysts. The consensus update has been recorded at $8.63. The standard deviation for short term price target has been estimated at $1.87. The higher price estimate and lower price estimate for the shares are recorded at $10 and $7 respectively. The 52 week high and 52 week low for the firm has been recorded at $6.3 and $0.0451.
Great Basin Scientific, Inc., a molecular diagnostic testing company, doing business as Great Basin Corporation, develops and commercializes molecular diagnostic systems that are designed to test hospital-attained infections.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
